Triplet Therapy Shows Promise for BPDCN, a rare blood cancer, in Dana-Farber Study
Childhood leukemia care puts one in three families at risk of poverty
Dana-Farber Cancer Institute drives deep remissions in Waldenstrom’s with targeted, time limited therapies
Chemo-free Regimens Show Promise, Could Redefine Care for B-Cell Lymphomas
Phase III VERONA trial results show potential benefit for some groups with myelodysplastic syndrome (MDS)
Sickle-cell disease associated with early onset of clonal hematopoiesis, a precancerous condition
Dana-Farber researchers to present findings at 2025 San Antonio Breast Cancer Symposium
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Research Points to Potential Gene Therapy Improvements
Three Ways Research Could Improve Pancreatic Cancer Treatment
FDA Approves Menin Inhibitor for Patients With Acute Leukemia With NPM1 Mutation, Backed by Dana-Farber Science
Pan-Mass Challenge Raises Record $78 Million for Dana-Farber Cancer Institute
Bringing Specialists Together: Tandem Leukemia and Stem Cell Transplant Consults
Showing 1 - 15 of 1049 results
Previous| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ...70 |Next
Cancer
Cardiology
Gastroenterology
Neurology
OBGYN
Orthopedics
Pediatrics
BroadcastMed News
Dermatology
Diabetes & Endocrinology
Infectious Diseases
Ophthalmology
Optometry
Otolaryngology
Pulmonology
Surgery
Urology
About
Solutions
Resources
Contact
person Sign In / Create Account
